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Change in Age 
Pattern of Persons 
with Dengue, 
Northeastern Brazil
To the Editor: Approximately 
40% of the world’s population is at risk 
for dengue (1). Epidemiologic charac-
teristics of dengue differ by region, 
and disease incidence varies by patient 
age. In Southeast Asia, incidence of 
dengue fever (DF) and dengue hemor-
rhagic fever (DHF) is highest among 
children (2,3); in the Western Hemi-
sphere, incidence of these diseases is 
higher among adults.
In Brazil, which has ≈80% of 
dengue cases in the Western Hemi-
sphere, adults are at risk for dengue 
virus (DENV) infection (3,4). Howev-
er, in 2007, a total of 53% of persons 
in Brazil hospitalized with DHF were 
children <15 years of age; this propor-
tion was highest (65.4%) in children 
in northeastern Brazil (5).
In Ceará, a state in northeast-
ern Brazil, DENV-1 epidemics have 
occurred since 1987. DHF cases 
have been reported since 1994 when 
DENV-2 was identiﬁ   ed. In 2003, a 
severe DENV-3 epidemic occurred, 
and DHF incidence was high among 
adults (6). However, since 2007, in-
cidence of DENV infection has been 
highest among children (7). To better 
understand factors that could affect 
this change in risk by age group, we 
studied the temporal progression of 
age distribution of persons with den-
gue during 1998–2008 in Ceará.
We used data for Ceará from the 
National System of Notiﬁ  able  Dis-
eases (DF and DHF cases), the Hos-
pital Admission Data System (dengue 
hospitalizations) (8), and the Central 
Public Health Laboratory (virus isola-
tion). For each age group (<10, 10–19, 
20–59, and >60 years), we calculated 
incidence of DF and hospitalization 
rate for DHF. We also calculated pro-
portions of dengue serotypes per year 
(2001–2008). Medians for continuous 
variables were compared by using the 
Kruskal-Wallis test. Analyses were 
performed by using Epi Info version 
6.0 software (Centers for Disease 
Control and Prevention, Atlanta, GA, 
USA).
From 1998 (10.8 cases/100,000 
persons) through 2007 (236.7 
cases/100,000 persons), DF incidence 
was lowest among persons <10 years 
of age. However, the incidence was 
highest (599.4 cases/100,000 persons) 
for this age group in 2008. In 2007, in-
cidence among persons <10 years of 
age (236.7 cases/100,000 persons) was 
similar to that among persons 10–19, 
20–59, and >60 years of age (305.6, 
331.5, and 249.9 cases/100,000 per-
sons, respectively).
Since 2007, the incidence of DHF 
among children was already higher 
(4,884 cases/100,000 persons) than 
among the other age groups (3,261, 
3,387 and 2,789 cases/100,000 per-
sons, respectively). In 2008, incidence 
of DHF among children was 8,992 
cases/100,000 persons, which was 2× 
that among persons 10–19 and 20–59 
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years of age and >3× that among per-
sons >60 years of age. Median age 
of persons with DHF decreased from 
38 years in 2001 to 18 years in 2008 
(p<0.0001). Children <10 years age, 
who in 2001 accounted for 5% of all 
cases, accounted for 33% of cases in 
2008.
The hospitalization rate for den-
gue among children in Ceará followed 
a pattern similar to that for DHF and 
increased for children <10 years of 
age. In 2008, this pattern was greater 
for this age group (1.449/1,000 hos-
pitalizations) than in any other age 
group. DENV-2 (52.3%) and DENV-1 
(47.7%) were co-circulating in 2002. 
DENV-3 was isolated in 2003 and 
represented >40% of isolations. At 
this time, DENV-2 and DENV-1 rep-
resented 7.4% and 48.5% of isola-
tions, respectively. DENV-3 then pre-
dominated in Ceará until 2006 when 
DENV-2 reemerged (1.4%). DENV-2 
became the predominant serotype in 
2007 (84%) and 2008 (76.1%) (Ta-
ble).
The increase in DHF incidence 
among children in Ceará during 
2007–2008 was greater than the over-
all increase in Brazil (4,5). Because 
the predominant serotype in Ceará in 
2007–2008 was DENV-2, two hypo-
theses may explain this phenomenon.
First, a more virulent DENV-2 
may have been introduced. Genetic 
sequencing of DENV-2 circulating 
in another state in Brazil during the 
2008 epidemic, compared with the 
1990 and 1998 epidemics, showed 
that all isolates had the same genotype 
(American/Asiatic); only a 2% had a 
phylogenetic change (9). Such a small 
difference cannot explain this change 
in the age group affected by dengue.
Second, the time when 3 sero-
types circulated in Ceará may not have 
favored development of antibodies 
against DENV-3 in children <10 years 
of age, although they were susceptible 
to DENV-2. DENV-1 and DENV-2 
were circulating in Ceará before 2002 
and caused DF epidemics and a few 
DHF cases. However, these diseases 
occurred predominantly in adults. 
Conversely, children had little likeli-
hood of being infected with DENV-2 
because the incidence of dengue be-
fore 2002 was low and the 2000 birth 
cohort had little contact with DENV-2, 
which was no longer circulating. Thus, 
most persons susceptible to DENV-2 
were children.
DENV-3 was circulating during 
2003–2006 and affected persons of all 
ages. Thus, when DENV-2 reemerged 
in 2006, many adults in Ceará already 
had antibodies against it. However, 
children had no antibodies against 
DENV-2, although some had antibod-
ies against DENV-3. This immuno-
logic difference may have caused the 
higher incidence of dengue among 
children in Ceará during 2007–2008, 
particularly in view of severity of the 
2 epidemics, increased risk for DHF 
(10), and number of hospitalizations 
for dengue during this period.
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Table. Confirmed cases of DF and DHF, Ceará, Brazil, 1998–2008* 
Characteristic 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 
No.  DF  cases  3,581  9,757  13,645 34,390 16,465 23,796  3,094  22,817 25,569 25,026 44,508 
No. DHF cases  4 3 4 82 72 292 14 199 173 280 408
Serotype of DENV isolated, % 
 1  – – – 47.7 48.5 1.9 0 2.5 0 0 0
 2  – – – 52.3 7.4 1.9 0 0.0 1.4 84.0 76.1
 3  – – – 0 44.1 96.2 100.0  97.5 98.6 16.0 23.9
Incidence of DF and DHF by age, y† 
  <10  10.8 37.8 65.4 174.7  78.5 128.0  14.3 126.5 116.0 236.7 599.4 
  10–19  26.7 95.4 129.3 321.4 160.6 250.4  34.3 198.2 247.9 305.6 574.4 
  20–59  68.3 198.7 263.6 659.3 304.3 416.9  53.6 365.2 412.6 331.5 521.9 
>60 143.1 210.0 194.8 423.4 223.3 313.0  39.1 441.5 422.2 249.9 301.0 
Incidence of DHF by age, y† 
  <10  0.000 0.000 0.000 0.236 0.114 1.423 0.068 1.011 0.890 4.884 8.992 
  10–19  0.062 0.000 0.059 0.796 0.449 3.601 0.065 2.512 1.771 3.261 4.968 
  20–59  0.064 0.094 0.058 1.361 1.474 4.655 0.318 3.074 3.053 3.387 4.358 
 > 60 0.174 0.000 0.152 1.890 1.289 5.134 0.000 2.650 0.832 2.789 2.868 
Hospitalizations for dengue (classic and hemorrhagic) by age, y‡ 
  <10  0.008 0.014 0.015 0.050 0.145 0.352 0.073 0.395 0.266 0.667 1.449 
  10–19  0.006 0.010 0.020 0.131 0.255 0.632 0.156 0.646 0.497 0.750 1.128 
  20–59  0.005 0.011 0.024 0.256 0.440 0.847 0.255 0.804 0.572 0.710 0.786 
 > 60 0.009 0.009 0.021 0.401 0.658 1.159 0.389 1.012 0.664 0.954 0.922 
*Source: Hospitalization Information System, Notifiable Disease Information System, and Central Public Health Laboratory of Ceará. DF, dengue fever; 
DHF, dengue hemorrhagic fever, DENV, dengue virus; –, no information. 
†Per 100,000 persons. 
‡Per 1,000 persons. LETTERS
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Apophysomyces 
variabilis Infections 
in Humans 
To the Editor: The fungus Apo-
physomyces elegans (order Mucorales) 
is a thermotolerant species that causes 
severe infections among humans. In 
contrast to other fungi that cause zy-
gomycosis, which have a worldwide 
distribution and are rarely found in 
immunocompetent hosts, A. elegans 
has been reported mainly in areas with 
warm climates as an emerging patho-
gen that causes mostly cutaneous in-
fections after injury to the skin (1). 
This fungus was discovered in 1979 
(2) and until recently was considered 
the only species in the genus.
A polyphasic study of clinical and 
environmental strains of A. elegans, 
including analysis of several genes, 
showed that the genus contained 4 
well-characterized species (3). Of 
16 isolates tested in this study, only 
2 from soil in India were A. elegans. 
Most of the isolates were A. variabi-
lis. The incidence of A. variabilis in 
humans is unknown and difﬁ  cult to 
ascertain because most cases had iso-
lates that were not properly preserved. 
These fungi usually cause necrotizing 
fasciitis, but rhino-orbito-cerebral or 
renal infections have also been report-
ed (1). Whether these infections are 
produced by different Apophysomyces 
spp., have different responses to an-
tifungal drugs, or have differences in 
virulence is unknown.
To assess incidence of Apophy-
somyces spp. in a tertiary hospital 
(Government Medical College Hospi-
tal, Chandigarh, India), which usually 
receives patients with zygomycosis, 
a retrospective study was conducted 
during November 2001–April 2009. 
Nine patients were identiﬁ  ed as having 
primary cutaneous zygomycosis. For 
4 patients, fungal isolates were mor-
phologically identiﬁ  ed as A. elegans. 
A description of clinical ﬁ  ndings, their 
management, and outcomes for these 
9 patients has been reported (4). The 
4 isolates were sent to the Universitat 
Rovira i Virgili (Reus, Spain) for mo-
lecular analysis.
The internal transcribed spacer 
region of these isolates was sequenced 
and compared with those of type 
strains of Apophysomyces spp. Fungi 
were identiﬁ  ed by morphologic (Fig-
ure, panel A) and molecular analysis as 
A. variabilis (99.6%–99.7% sequence 
identity with sequence of type strain 
CBS 658.93 [FN556436]). GenBank 
accession nos. of the 4 isolates are 
FN813491, FN813490, FN556442, 
and FN813492.
Another patient was also infected 
with A. variabilis fungi. The patient 
was a 45-year-old woman with dia-
betes from Derabassi (Punjab), India, 
who was hospitalized because of swell-
ing in her right breast and blackening 
of overlying skin. A diagnosis of right 
breast gangrene was made. Therefore, 
local debridement of the swelling was 
conducted, and tissue samples were 
tested by microbiologic culture and 
histopathologic analysis.
A KOH wet mount showed broad 
aseptate hyphae with right-angled 
branching. The fungal isolate was 
tentatively identiﬁ  ed  as  A. elegans. 
Histopathologic analysis conﬁ  rmed 
a diagnosis of zygomycosis. The pa-
tient was treated under local anesthe-
sia by debridement of infected tissue 
and some of the healthy surrounding 
tissue (Figure, panel B). However, an 
antifungal regimen could not be given 
because she had disturbed renal func-
tion. Her condition deteriorated, sep-
ticemia was observed, and she died 
from sudden cardiac arrest on the sixth 
day after admission. The fungal iso-
late was also identiﬁ  ed as A. variabilis 
(98.9% identity, GenBank accession 
no. FN556443).
Although most cases of infection 
with  A. variabilis fungi have been 
reported in India (5), infections with 
this fungus may have a wider distribu-
tion. A recent study demonstrated that 
this species represented 0.5% of fungi 
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